Powerful clinical efficacy across patient groups

In 1st or later line with fulvestrant
In PALOMA-3, IBRANCE® + fulvestrant in 1st or later line demonstrated PFS improvements vs placebo + fulvestrant in pre-menopausal patients*2

  • In PALOMA-3, 21% of patients treated with IBRANCE® + fulvestrant were pre-/peri-menopausal†2


Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Loibl S, et al. 2016.2
Data cut-off date: March 16, 2015.
*Evaluated according to RECIST Version 1.1.3 †Pre-/peri-menopausal patients enrolled in PALOMA-3 received the LHRH agonist goserelin for at least 4 weeks prior to and for the duration of the trial.2

CI = confidence interval; FUL = fulvestrant; HR = hazard ratio; LHRH = luteinising hormone-releasing hormone; = number of patients; NE = not estimable; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.

  1. IBRANCE® Summary of Product Characteristics.
  2. Loibl S, et al. Oncologist. 2017;22(9):1028-1038.
  3. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.

©2020 Pfizer. All rights reserved. PP-IBR-IRL-0501 Date of Preparation: March 2022 Legal Category: S1A